Company: HCTI
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076686
Chunk: 20

Company: Healthcare Triangle, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 20
---
”)
with institutional investors (the “Investors”) for the private placement of 145,344 units (each a, “Unit”), each
Unit consisting of one share of the Company’s common stock (“Common Stock”) or one pre-funded warrant (a “Pre-Funded
Warrant”) to purchase one share of common stock, one Series A Warrant (a “Series A Warrant”) to purchase one share of
common stock and one Series B Warrant (a “Series B Warrant” and together with the Series A Warrant, the “Purchase Warrants”)
to purchase one share of common stock at an offering price of $104.58 per Unit (or $104.58 per Unit in the case of Units that include
pre-funded warrants). The Common Stock, the Pre-Funded Warrants and the Purchase Warrants included in the Units and the Common Stock underlying
the Pre-Funded Warrants and the Purchase Warrants are collectively referred to herein as the “Securities” and the Securities,
other than the Pre-Funded Warrants, and the Purchase Warrants shall be referred to herein as the “Registrable Securities.”
The entire transaction has been priced at the market under Nasdaq rules and closed on February 28, 2025. 

The initial exercise price for both the Series
A Warrants and Series B Warrants is $209.16 per share and both terminate on the fifth anniversary of the later of (x) effective date of
stockholder approval and (y) the earlier of (i) the effective date of the registration statement (the “Registration Statement”)
filed by the Company to register the Registerable Securities or (ii) the date that the Registerable Securities can be sold, assigned or
transferred without restriction or limitation pursuant to Rule 144 promulgated under the 1933 Act, as amended. The Purchase Warrants may
not be exercised until stockholder approval of the exercise of the Purchase Warrants is effective (“Stockholder Approval”).
The Company has agreed in the Purchase Agreement to obtain Stockholder Approval within 60 days of the closing date of the offering.

The Company received gross proceeds of approximately
$15,200 . Net proceeds to the Company were approximately $13,676 , after deducting placement agent fees and other expenses payable by
the Company.

The Company allocated the proceeds between the
Common Stock, Pre-Funded Warrants, and Common Warrants (some of which were exercisable on cash basis, whereas